NCT02697552View on ClinicalTrials.gov

Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

HBI-8000

Oral doses of 30mg, 40mg, 50mg twice weekly \[BIW\].

Trial Locations (8)

Unknown

Nagoya City University Hospital, Aichi

Fukuoka University Hospital, Fukuoka

NHO Kyushu Cancer Center, Fukuoka

Kagoshima University Medical and Dental Hospital, Kagoshima

Tokai University Hospital, Kanagawa

NHO Kumamoto Medical Center, Kumamoto

NHO Nagasaki Medical Center, Nagasaki

National Cancer Center Hospital, Tokyo

All Listed Sponsors
lead

HUYABIO International, LLC.

INDUSTRY

NCT02697552 - Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter